alny interfrx options

Benitec's InterfRx licence options have to have gone up in value if analysts are re-rating Alny as a buy. We've got 5 - got to be somewhere between $10M to $50M each, i'd have thought the latter given Alny's breakthrough clinical data.

Also worth noting the Alny 5x15 programme does not have a single disease target that conflicts with Benitec programme.

http://community.nasdaq.com/News/2011-11/alnylam-reveals-alnttr01-trial-data-analyst-blog.aspx?storyid=104992